Capsule: Each capsule contains: Carbocisteine 500 mg.
Pediatric Syrup: 100 mg/5 mL Syrup.
Infant Drops: 50 mg/mL Syrup (Oral Drops).
These medicines contain the active ingredient Carbocisteine, a mucolytic agent.
Excipients/Inactive Ingredients: Capsule: It also contains starch (10 mg) subcomponent and gelatin capsule (may contain allergens like soybeans, sulfur dioxide, sulphites, artificial colorants, latex, lecithin, alcohols and products thereof) which may cause allergic reactions.
Capsule: This product is used as adjunctive mucolytic therapy for respiratory tract disorders characterized by excessive or viscous mucous, such as acute and chronic bronchitis, bronchiectasis, asthmatic bronchitis and emphysema. Adjunctive therapy in otorhinolaryngology for otitis, sinusitis, nasopharyngitis, tubal otorrhea and for reducing hypersecretion prior to surgery.
Pediatric Syrup/Infant Drops: Carbocisteine (Loviscol) is used as adjunctive therapy for chronic disorders of the respiratory tract associated with excessive or viscous mucus, such as chronic bronchitis, chronic obstructive pulmonary disease and otitis media with effusion including glue ear.
Capsule: One capsule every 8 hours or 3 times a day or as prescribed by a physician.
Pediatric Syrup: See table.
Click on icon to see table/diagram/image
Infant Drops: 13-24 months: 1.2 mL every 6 hours or as prescribed by physician.
Reports of overdosage with Carbocisteine do not provide consistent data regarding the signs and symptoms of overdose.
There is no known antidote for overdosage. Treatment is symptomatic and supportive. If vomiting has not occurred it should be induced by conventional means or gastric lavage may be instituted. In case of accidental overdose or at the first sign of any adverse reaction, discontinue use and seek professional assistance immediately.
These products are contraindicated in patients with active peptic ulcer and in cases of known hypersensitivity to Carbocisteine or any of the components of the product.
Taking of multiple antitussive agents with Carbocisteine is not recommended.
Patients with a history of peptic ulceration should be examined prior to carbocisteine administration to exclude the presence of an active ulcer.
Do not exceed recommended daily dose.
Use in Pregnancy: The safety of Carbocisteine for use during pregnancy has not been established. It should not be used in pregnant women unless, in the judgment of the physician, the expected benefits substantially outweigh the potential risk to the fetus.
Capsule: Endocrine disorders: Transient hypothyroidism in a patient with compromised thyroid function.
Nervous System disorders: Headache Gastrointestinal disorders: mild gastrointestinal symptoms such as nausea, diarrhea, gastric discomfort which often subside on lowering the dose or discontinuing the treatment, gastrointestinal bleeding has also been reported.
Skin and Subcutaneous Tissue disorders: Allergic reactions including occasional skin rash and urticaria, angioedema.
Pediatric Syrup/Infant Drops: Nausea, diarrhea, gastric discomfort, gastrointestinal bleeding, and skin rash have occasionally occurred.
Dilution with syrups containing pholcodine will cause precipitation.
The use of concomitant antitussive agents is not recommended.
In human studies, no interaction has been found between carbocisteine and antibiotics, antihistamines or costicosteroids.
Capsule: Store at temperatures not exceeding 30°C, away from direct sunlight.
Pediatric Syrup/Infant Drops: Store at temperatures not exceeding 25°C, away from direct sunlight.
R05CB03 - carbocisteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
Loviscol cap 500 mg
100's (P1,375/pack)
Loviscol Infant oral drops 50 mg/mL
15 mL x 1's (P97.75/bottle)
Loviscol Ped syr 100 mg/5 mL
120 mL x 1's (P159.25/bottle);60 mL x 1's (P102.5/bottle)
Sign Out
Click on icon to see table/diagram/image
